Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Stem cells

Low-risk reprogramming

Nature volume 458, pages 715–716 (2009)Cite this article

New techniques circumvent a roadblock to the production of embryonicstem-cell-like lines from adult tissue. Such reprogrammed cell lines should be much safer to use for therapy.

Shinya Yamanaka's amazing discovery1 that cells from differentiated tissues can be reprogrammed into induced pluripotent stem (iPS) cells — cells that can potentially differentiate into any cell type — has transformed research in stem-cell biology and regenerative medicine. The breakthrough provided both a deft approach to the production of patient-specific stem-cell lines with which to study disease, and a practical means of developing large banks of stem-cell lines suitable for tissue matching in transplantation therapy. But the original protocols for producing iPS cells relied on the integration of foreign 'reprogramming' genes into the host-cell genome, a process associated with risks including mutation, dysregulation of native gene expression, and the development of cancers after iPS-cell transplantation. Four studies2,3,4,5, including two in this issue2,3, now show that iPS cells can be produced without any permanent modification to the host-cell genome.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Takahashi, K. & Yamanaka, S. Cell 126, 663–676 (2006).

    Article  CAS  Google Scholar 

  2. Woltjen, K. et al. Nature 458, 766–770 (2009).

    Article  ADS  CAS  Google Scholar 

  3. Kaji, K. et al. Nature 458, 771–775 (2009).

    Article  ADS  CAS  Google Scholar 

  4. Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. & Hochedlinger, K. Science 322, 945–949 (2008).

    Article  ADS  CAS  Google Scholar 

  5. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T. & Yamanaka, S. Science 322, 949–953 (2008).

    Article  ADS  CAS  Google Scholar 

  6. Takahashi, K. et al. Cell 131, 861–872 (2007).

    Article  CAS  Google Scholar 

  7. Yu, J. et al. Science 318, 1917–1920 (2007).

    Article  ADS  CAS  Google Scholar 

  8. Okita, K., Ichisaka, T. & Yamanaka, S. Nature 448, 313–317 (2007).

    Article  ADS  CAS  Google Scholar 

  9. Zhou, Q. & Melton, D. A. Cell Stem Cell 3, 382–388 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Martin F. Pera is at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA. martin.pera@keck.usc.edu ,

    Martin F. Pera

Authors
  1. Martin F. Pera
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pera, M. Low-risk reprogramming. Nature 458, 715–716 (2009). https://doi.org/10.1038/458715a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/458715a

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing